http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110305125-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate | 2019-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110305125-B |
| titleOfInvention | 5-pyrimidine-6-oxy-pyrazolopyridine derivative and preparation method and application thereof |
| abstract | The invention relates to a 5-pyrimidine-6-oxygen-pyrazolopyridine derivative, a pharmaceutically available salt thereof, a preparation method and an application thereof, wherein the chemical structural formula (II) of the 5-pyrimidine-6-oxygen-pyrazolopyridine derivative is shown as the following formula: the derivatives and pharmaceutically acceptable salts thereof block TGF-beta/ERK signal pathways by activating sGC-cGMP pathways, thereby exerting anti-fibrosis effects. Therefore, the novel sGC agonist can be used as a novel sGC agonist, plays the roles of resisting fibrosis and tissue remodeling by up-regulating the cGMP level, and becomes a novel strategy for treating pulmonary fibrosis diseases. |
| priorityDate | 2019-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 281.